ten Bosch John Roderick sold $321K of BLLN

ten Bosch John Roderick (SVP of Laboratory Operations) sold 2,834 shares of BillionToOne, Inc. (BLLN) at $113.17 ($0.32M total) across 2 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ten Bosch John Roderick
Published Nov 5, 2026, 1:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The disclosed sale adds a new data point for investors monitoring insider sentiment.

02

Market read

A modest insider sell that may prompt short‑term price pressure but is unlikely to move the stock significantly.

03

What to watch

Potential tax planning or diversification needs of the insider.

Relevance 3/10Novelty 3/10Timing: after-hours on 2026-11-02

Background

SEC Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

Form 4 disclosed that SVP John Roderick sold 2,834 shares of BillionToOne for $320,724 on 2026-11-02.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

The sale is modest in size but indicates the insider is reducing exposure, which can be interpreted as a bearish signal.

Market effects

Minimal impact on the broader biotech sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

The sale may be unrelated to company fundamentals and could be a routine liquidity move.

Key entities

  • BillionToOne, Inc.

    Biotech company listed on US exchanges under ticker BLLN.

  • John Roderick

    SVP of Laboratory Operations at BillionToOne, reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.